Jamie L Harden1, Steven M Lewis2, Samantha R Lish2, Mayte Suárez-Fariñas3, Daniel Gareau2, Tim Lentini2, Leanne M Johnson-Huang2, James G Krueger2, Michelle A Lowes4. 1. Laboratory for Investigative Dermatology, Rockefeller University, New York, NY. Electronic address: jharden@rockefeller.edu. 2. Laboratory for Investigative Dermatology, Rockefeller University, New York, NY. 3. Laboratory for Investigative Dermatology, Rockefeller University, New York, NY; Center for Clinical and Translational Science, Rockefeller University, New York, NY; Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY. 4. Laboratory for Investigative Dermatology, Rockefeller University, New York, NY; Division of Dermatology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.
Abstract
BACKGROUND: Many human diseases arise from or have pathogenic contributions from a dysregulated immune response. One pathway with immunomodulatory ability is the tryptophan metabolism pathway, which promotes immune suppression through the enzyme indoleamine 2,3-dioxygenase (IDO) and subsequent production of kynurenine. However, in patients with chronic inflammatory skin disease, such as psoriasis and atopic dermatitis (AD), another tryptophan metabolism enzyme downstream of IDO, L-kynureninase (KYNU), is heavily upregulated. The role of KYNU has not been explored in patients with these skin diseases or in general human immunology. OBJECTIVE: We sought to explore the expression and potential immunologic function of the tryptophan metabolism enzyme KYNU in inflammatory skin disease and its potential contribution to general human immunology. METHODS: Psoriatic skin biopsy specimens, as well as normal human skin, blood, and primary cells, were used to investigate the immunologic role of KYNU and tryptophan metabolites. RESULTS: Here we show that KYNU(+) cells, predominantly of myeloid origin, infiltrate psoriatic lesional skin. KYNU expression positively correlates with disease severity and inflammation and is reduced on successful treatment of psoriasis or AD. Tryptophan metabolites downstream of KYNU upregulate several cytokines, chemokines, and cell adhesions. By mining data on several human diseases, we found that in patients with cancer, IDO is preferentially upregulated compared with KYNU, whereas in patients with inflammatory diseases, such as AD, KYNU is preferentially upregulated compared with IDO. CONCLUSION: Our results suggest that tryptophan metabolism might dichotomously modulate immune responses, with KYNU as a switch between immunosuppressive versus inflammatory outcomes. Although tryptophan metabolism is increased in many human diseases, how tryptophan metabolism is proceeding might qualitatively affect the immune response in patients with that disease.
BACKGROUND: Many human diseases arise from or have pathogenic contributions from a dysregulated immune response. One pathway with immunomodulatory ability is the tryptophan metabolism pathway, which promotes immune suppression through the enzyme indoleamine 2,3-dioxygenase (IDO) and subsequent production of kynurenine. However, in patients with chronic inflammatory skin disease, such as psoriasis and atopic dermatitis (AD), another tryptophan metabolism enzyme downstream of IDO, L-kynureninase (KYNU), is heavily upregulated. The role of KYNU has not been explored in patients with these skin diseases or in general human immunology. OBJECTIVE: We sought to explore the expression and potential immunologic function of the tryptophan metabolism enzyme KYNU in inflammatory skin disease and its potential contribution to general human immunology. METHODS: Psoriatic skin biopsy specimens, as well as normal human skin, blood, and primary cells, were used to investigate the immunologic role of KYNU and tryptophan metabolites. RESULTS: Here we show that KYNU(+) cells, predominantly of myeloid origin, infiltrate psoriatic lesional skin. KYNU expression positively correlates with disease severity and inflammation and is reduced on successful treatment of psoriasis or AD. Tryptophan metabolites downstream of KYNU upregulate several cytokines, chemokines, and cell adhesions. By mining data on several human diseases, we found that in patients with cancer, IDO is preferentially upregulated compared with KYNU, whereas in patients with inflammatory diseases, such as AD, KYNU is preferentially upregulated compared with IDO. CONCLUSION: Our results suggest that tryptophan metabolism might dichotomously modulate immune responses, with KYNU as a switch between immunosuppressive versus inflammatory outcomes. Although tryptophan metabolism is increased in many human diseases, how tryptophan metabolism is proceeding might qualitatively affect the immune response in patients with that disease.
Authors: Jamie L Harden; Tao Gu; Mehmet O Kilinc; Rachael B Rowswell-Turner; Lauren P Virtuoso; Nejat K Egilmez Journal: J Immunol Date: 2011-06-01 Impact factor: 5.422
Authors: Christiane A Opitz; Ulrike M Litzenburger; Felix Sahm; Martina Ott; Isabel Tritschler; Saskia Trump; Theresa Schumacher; Leonie Jestaedt; Dieter Schrenk; Michael Weller; Manfred Jugold; Gilles J Guillemin; Christine L Miller; Christian Lutz; Bernhard Radlwimmer; Irina Lehmann; Andreas von Deimling; Wolfgang Wick; Michael Platten Journal: Nature Date: 2011-10-05 Impact factor: 49.962
Authors: Francesca Fallarino; Ursula Grohmann; Sylvaine You; Barbara C McGrath; Douglas R Cavener; Carmine Vacca; Ciriana Orabona; Roberta Bianchi; Maria L Belladonna; Claudia Volpi; Pere Santamaria; Maria C Fioretti; Paolo Puccetti Journal: J Immunol Date: 2006-06-01 Impact factor: 5.422
Authors: Christabelle J Darcy; Joshua S Davis; Tonia Woodberry; Yvette R McNeil; Dianne P Stephens; Tsin W Yeo; Nicholas M Anstey Journal: PLoS One Date: 2011-06-22 Impact factor: 3.240
Authors: Michael Camilleri; Paula Carlson; Nelson Valentin; Andres Acosta; Jessica O'Neill; Deborah Eckert; Roy Dyer; Jie Na; Eric W Klee; Joseph A Murray Journal: Am J Physiol Gastrointest Liver Physiol Date: 2016-07-21 Impact factor: 4.052
Authors: Lam C Tsoi; Elke Rodriguez; Dora Stölzl; Ulrike Wehkamp; Jingru Sun; Sascha Gerdes; Mrinal K Sarkar; Matthias Hübenthal; Chang Zeng; Ranjitha Uppala; Xianying Xing; Frederieke Thielking; Allison C Billi; William R Swindell; Alanna Shefler; Jiahan Chen; Matthew T Patrick; Paul W Harms; J Michelle Kahlenberg; Bethany E Perez White; Emanual Maverakis; Johann E Gudjonsson; Stephan Weidinger Journal: J Allergy Clin Immunol Date: 2019-12-28 Impact factor: 10.793
Authors: Hui Xing Lau; Sarah El-Heis; Qai Ven Yap; Yiong Huak Chan; Cheryl Pei Ting Tan; Neerja Karnani; Karen Mei Ling Tan; Elizabeth Huiwen Tham; Anne Eng Neo Goh; Oon Hoe Teoh; Kok Hian Tan; Johan Gunnar Eriksson; Yap Seng Chong; Mary Foong-Fong Chong; Hugo Van Bever; Bee Wah Lee; Lynette P Shek; Keith M Godfrey; Evelyn Xiu Ling Loo Journal: Clin Exp Allergy Date: 2021-06-24 Impact factor: 5.018
Authors: Danay Cibrian; María Laura Saiz; Hortensia de la Fuente; Raquel Sánchez-Díaz; Olga Moreno-Gonzalo; Inmaculada Jorge; Alessia Ferrarini; Jesús Vázquez; Carmen Punzón; Manuel Fresno; Miguel Vicente-Manzanares; Esteban Daudén; Pedro M Fernández-Salguero; Pilar Martín; Francisco Sánchez-Madrid Journal: Nat Immunol Date: 2016-07-04 Impact factor: 25.606